Medication compliance and disease exacerbation in patients with asthma: A retrospective study of managed care data

Annals of Allergy, Asthma and Immunology

Volumn 97, Issue 3, 2006, Pages 402-408

  Stern, Lee ^a   Berman, Jeff ^b   Lumry, William ^c   Katz, Laura ^a   Wang, Lujing ^a   Rosenblatt, Lisa ^a   Doyle, John J ^a  

^a Global Health Outcomes   (United States)

^b Nova Southeastern University   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CORTICOSTEROID DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; SHORT ACTING DRUG; THEOPHYLLINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CHILD; DISEASE EXACERBATION; EMERGENCY TREATMENT; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 33749160805     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60808-3     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. Asthma prevashy; lence, health care use, and mortality, 2002. Available at: http://shy; www.cdc.gov/nchs/data/asthmahealthestat.pdf. Accessed April 10, 2005.
2. Johnson B, Wiesemann S, Andersen J. Using a matrix as an educational approach to asthma. J Pediatr Health Care. 2003;shy; 17:3-10.
3. American Lung Association. Asthma Fact Sheet 1998. New York, NY: American Lung Association; 1998.
4. Skrepnek GH, Skrepnek SV. Epidemiology, clinical and ecoshy; nomic burden, and natural history of chronic obstructive pulshy; monary disease and asthma. Am J Manag Care. 2004;10:shy; S129-S138.
5. American Lung Association, Epidemiology and Statistics Unit, Research and Scientific Affairs. Trends in Asthma Morbidity and Mortality, 2004. New York, NY: American Lung Association; 2005.
6. American Lung Association. Asthma in adults fact sheet. Availshy; able at: http://www.lungusa.org/site/pp.asp?c=dvLUK9O0E­ b=22596. April 10, 2005.
7. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/ shy; asthgdln.htm.
8. Hunter MH, King DE. COPD: management of acute exacerbashy; tions and chronic stable disease. Am Fam Physician. 2001;64:shy; 603-612.
9. Sullivan SD. Asthma in the United States: recent trends and current status. J Manag Care Pharm. 2003;9:3-7.
10. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004;92:32-39.
11. Creer TL, Levstek D. Medication compliance and asthma: overshy; looking the trees because of the forest. J Asthma. 1996;33:shy; 203-211.
12. Ehrlich RI, Du Toit D, Jordaan E, et al. Risk factors for childhood asthma and wheezing: importance of maternal and household smoking. Am J Respir Crit Care Med. 1996;154:shy; 681-688.
13. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medicashy; tions. Arch Intern Med. 1994;154:1349-1352.
14. Kemp JP, Kemp JA. Management of asthma in children. Am Fam Physician. 2001;63:1341-1348, 1353-1354.
15. Gendo K, Lodewick MJ. Asthma economics: focusing on thershy; apies that improve costly outcomes. Curr Opin Pulm Med. 2005;11:43-50.
16. Liljas B, Lahdensuo A. Is asthma self-management cost-shy; effective? Patient Educ Couns. 1997;32:S97-S104.
17. Ringdal N, Chuchalin A, Chovan L, Tudoric N, Maggi E, Whitehead PJ. Evaluation of different inhaled combination thershy; apies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd) Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. Respir Med. 2002;96:851-861.
18. Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. J Manag Care Pharm. 2004;10:122-129.
19. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan thershy; apy in a usual-care setting. J Manag Care Pharm. 2003;9:shy; 424-429.
20. Schatz M, Nakahiro R, Jones CH, Roth RM, Joshua A, Petitti D. Asthma population management: development and validation of a practical 3-level risk stratification scheme. Am J Manag Care. 2004;10:25-32.
21. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:shy; 245-251.
22. Hampson NB, Mueller MP. Reduction in patient timing errors using a breath-activated metered dose inhaler. Chest. 1994;106:shy; 462-465.
23. American Lung Association. Search LungUSA. Available at: http://www.lungusa.org/site/apps/s/content.asp?c=dvLUK9O0E­ b=34706&ct=910853. April 10, 2005.
24. Dolovich MB, Ahrens RC, Hess DR, et al; American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127:335-371.